A cross-sectional analysis of joint status and quality of life in children and adolescents with haemophilia in Romania.

BACKGROUND Haemophilia is a congenital disorder of coagulation with high economic burden due to its requirement for an expensive, lifelong replacement therapy, with additional costs for the frequent complications and for the severe handicapping consequences. The objective of this cross-sectional study aimed at giving an insight into the health condition of young haemophiliacs in the absence of a regular prophylactic therapy. METHODS It was conducted on a heterogeneous group of 37 children and adolescents (4-24 years of age), with similar on demand therapeutic regimen, coming from the whole country, focusing on the joint status by using the Haemophila Joint Health Score (HJHS) system and on quality of life (QoL) by using the EQ-5D-3L-Y questionnaire. RESULTS The results revealed an impressive situation: 70.3 % with chronic arthropathy, 19 % with target joints, 69 % with multiple joint involvement, mainly elbow (41 %) and knee (34 %), joint damage starting in the age group 6-12 years (18.18 % arthropathy vs. 96 % in the age group above 12 years). Joint score (6.67 ± 7.92), gait score (0.75 ± 1.14) and HJHS (7.43 ± 8.78) were highly correlated (r = 0.7, p = 0.001) with the annualised bleeding rate ABR (16.2 ± 12.1). They impacted the QoL in all domains, also expressed by a VAS of 68.39 ± 21.6. CONCLUSION We concluded that in the situation of an international consensus that prophylactic replacement can prevent cost-effectively and cost-efficiently the deleterious joint damages, our study is supporting the introduction even of secondary and tertiary prophylaxis in young patients in our country.

[1]  Adrienne Lee,et al.  Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? , 2016, Thrombosis Journal.

[2]  Y. T. van der Schouw,et al.  Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates , 2016, Thrombosis and Haemostasis.

[3]  J. Windyga Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia? , 2016, Seminars in Thrombosis & Hemostasis.

[4]  J. Oldenburg Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. , 2015, Blood.

[5]  R. Ljung,et al.  Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades , 2015, Haematologica.

[6]  Y. Janu,et al.  Joint Health Status of Hemophilia Patients in Jodhpur Region , 2015, Indian Journal of Hematology and Blood Transfusion.

[7]  M. Ozelo,et al.  Musculoskeletal evaluation in severe haemophilia A patients from Latin America , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Gill,et al.  The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia , 2013, British journal of haematology.

[9]  R. Engelbert,et al.  Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score , 2011, Arthritis care & research.

[10]  G. Auerswald,et al.  New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Stonebraker,et al.  A study of reported factor VIII use around the world , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[13]  B. Feldman,et al.  Hemophilia joint health score reliability study , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  P. Giangrande,et al.  Clinical outcomes and resource utilization associated with haemophilia care in Europe , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  C. Kessler,et al.  When should prophylactic treatment in patients with haemophilia A and B start?— The German experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[17]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.